Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | FOXO1 | Q12778 | 6/20 | 0.55 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.54 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | COMT | P21964 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22489011 | 0.92 | MMP2 (0.59) | NPC1RAB9AFOXO1HPSEKDM4E | |
| SCHEMBL22488747 | 0.90 | ADORA2A (0.60) | NPC1RAB9AFOXO1HPSEKDM4E | |
| SCHEMBL24513591 | 0.90 | NPC1 (0.60) | NPC1RAB9AFOXO1HPSEKDM4E | |
| SCHEMBL22488976 | 0.90 | NPC1 (0.60) | NPC1RAB9AFOXO1HPSEKDM4E | |
| SCHEMBL22488975 | 0.89 | NPC1 (0.65) | NPC1RAB9AFOXO1KDM4EMEN1 | |
| SCHEMBL22488757 | 0.87 | FOXO1 (0.70) | NPC1RAB9AFOXO1HPSEKDM4E | |
| SCHEMBL24513213 | 0.87 | FOXO1 (0.52) | NPC1RAB9AFOXO1HPSEKDM4E | |
| SCHEMBL22489164 | 0.87 | COMT (0.64) | NPC1RAB9AFOXO1HPSEKDM4E | |
| SCHEMBL22489134 | 0.87 | FOXO1 (0.58) | NPC1RAB9AFOXO1HPSEKDM4E | |
| SCHEMBL22488977 | 0.84 | PDE10A (0.57) | FOXO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185797-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-06-16 | — | — | US | disclosed |
| WO-2020198351-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185797-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | FOXO1, FOXO3, FOXK1 | NPC1 3743/4885RAB9A 1948/4885FOXO1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.